Chester County News and Community Website
CONSHOHOCKEN, PA — Madrigal Pharmaceuticals Inc. (NASDAQ: MDGL) has secured three new U.S. patents for its liver disease drug Rezdiffra, extending intellectual property protection for key treatment methods through as …
Madrigal Expands Rezdiffra Patent Portfolio Into 2045 Read More
WASHINGTON, D.C. — The U.S. Food and Drug Administration approved Hepcludex as the first authorized treatment for chronic hepatitis delta virus infection in the United States, giving patients with the …
FDA Clears First Hepatitis Delta Treatment for U.S. Market Read More CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) unveiled new two-year data showing that its flagship therapy Rezdiffra produced sustained improvements in patients with compensated MASH cirrhosis, a population with …
Breakthrough Liver Drug Shows Powerful Two-Year Gains — But Raises a Critical Warning Read More CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) announced that it will present multiple new analyses on its MASH therapy, Rezdiffra (resmetirom), at the upcoming American Association for the Study …
Madrigal to Unveil New Rezdiffra Data at Key Liver Disease Conference Read More CONSHOHOCKEN, PA — Madrigal Pharmaceuticals (NASDAQ: MDGL) announced Monday it has secured exclusive global rights to develop and commercialize SYH2086, a preclinical oral GLP-1 receptor agonist, through a licensing deal with …
Madrigal Licenses Oral GLP-1 Drug From CSPC, Targets Next-Gen MASH Therapy Read More
WASHINGTON, D.C. — The U.S. Department of Health and Human Services (HHS) has issued a final rule designed to expand access to kidney and liver transplants for patients with HIV. By …
HHS Finalizes Rule to Expand Kidney and Liver Transplants for Individuals with HIV Read More